Acute promyelocytic leukaemia:a review

Bibliography

• VARDIMAN JVV, HARRIS NL, BRUNNING RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood(2002) 100(7):2292–2302.
   PubMedGoogle Scholar
• KANTARJIAN HM, KEATING M, WALTERS RS: Acute promyelocytic leukemia, MD Anderson Hospital experience. Am. J. Med. (1997) 80:789–797.
   Web of Science ®Google Scholar
• LU DP: Treatment of leukemia. Science publishers, Beijing, China (1992):152.
   Google Scholar
• DOUER D, PRESTON-MARTIN S, KEUNG YK et al.: High occurrence of FAB M3 subtype among acute myelocytic leukemia (AML) patients of Latino origin. Blood (1994) 84(Suppl.):1 a.
   Google Scholar
• CHEN Z, TONG JH, DONG S et al: Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. Genes Chromosomes Cancer (1996) 15(3):147–156.
   PubMedGoogle Scholar
• •Gives a good description of the pathogenesis of APL and understanding of the retinoic acid pathway.
   Google Scholar
• CHEN SJ, WANG ZY AND CHEN Z: Acute promyelocytic leukemia: from clinic to molecular biology. Stem Cells (1995) 13(1):22–31.
   PubMedGoogle Scholar
• BERNARD J, WEIL M, BOIRON M et al.: Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood (1973) 41(0489–496.
   PubMed Web of Science ®Google Scholar
• COLLINS AJ, BLOOMFIELD CD, PETERSON BA et al: Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction. Arch. Intern. Med. (1978) 138(11):1677–1680.
   Google Scholar
• MARTY M, GANEM G, FISHER J et al: (Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin). Nouv. Rev Fr. Hematol (1984) 26(6):371–378.
   PubMedGoogle Scholar
• PETTI MC, AVVISATI G, AMADORI S et al.: Acute promyelocytic leukemia: clinical aspects and results of treatment in 62 patients. Haematologica (1987) 72(2):151–155.
   PubMedGoogle Scholar
• SANZ MA, JARQUE I, MARTIN G et al: Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer (1988) 61(1):7–13.
   Google Scholar
• AVVISATI G, PETTI MC, LO-COCO F et al.: Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood (2002) 100(9):3141–3146.
   PubMed Web of Science ®Google Scholar
• HEAD D, KOPECKY KJ, WEICK J et al:Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood (1995) 86(5):1717–1728.
   PubMed Web of Science ®Google Scholar
• •Important study showing higher doses of daunorubicin are associated with a prolonged overall survival, DFS and CR rates.
   Google Scholar
• HUANG ME, YE YC, WANG ZY: Treatment of four APL patients with all-trans retinoic acid. Chin. I Intern. Med. (1987) 26:330–332.
   PubMedGoogle Scholar
• SUN HD, MA L, HU XC, ZHANG TD: Treatment of acute promyelocytic leukemia by A1-1 therapy. Chin. I Integral-. Chin. Trad. Med. Western Med. (1992) 12:170–172.
   Google Scholar
• HUANG ME, YE YC, CHEN SR et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood (1988) 72(2):567–572.
   PubMed Web of Science ®Google Scholar
• WANG ZY, SUN GL, YE YC et al: Treatment of acute promyelocytic leukemia with all-trans retinoic acid, results of 90 cases. Chin. J. Hematol (1990) 11:480.
   Google Scholar
• SUN GL, HUANG YG, CHANG XF et al.: Clinical study on all-trans retinoic acid in the treatment of 544 patients with acute promyelocytic leukemia. Chinese Cooperative Study Group on APL. Chin. J. Hematol (1992) 13:135–137.
   Google Scholar
• CHEN ZX, XUE YQ, ZHANG R et al: A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood(1991) 78(6):1413–1419.
   PubMed Web of Science ®Google Scholar
• CASTAIGNE S, CHIOMIENNE C, DANIEL MT et al.: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood (1990) 76(9):1704–1709.
   PubMed Web of Science ®Google Scholar
• WARRELL RP, FRANKEL SR, MILLER WH et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl. Med. (1991) 324(20):1385–1393.
   PubMed Web of Science ®Google Scholar
• ••An important study of 11 patients, whichshowed tretinoin to be a safe and highly effective agent for inducing CR in patients with APL.
   Google Scholar
• OHNO R, YOSHIDA H, FUKUTANI H et al.: Multi-interinstitutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia (1993) 7:1722–1727.
   PubMed Web of Science ®Google Scholar
• KANAMARU A, TAKEMOTO Y, TANIMOTO M et al.: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood (1995) 85(5):1202–1206.
   Google Scholar
• •An important study of 110 patients, in which ATRA with or without chemotherapy gave a statistical improvement in CR rate and early mortality rate, as well as superior survival in newly diagnosed APL.
   Google Scholar
• TALLMAN MS, ANDERSON JW, SCHIFFER CA et al.: All-trans-retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med (1997) 337(15):1021–1028.
   PubMed Web of Science ®Google Scholar
• ••First randomised study to show that ATRAwith or without chemotherapy gives a statistical improvement in CR rate and early mortality rate, as well as superior survival in newly diagnosed APL.
   Google Scholar
• SOIGNET SL, FLEISCHAUER A, POLYAK T et al.: All-Trans retinoic acid significantly increases 5 year survival in patients with acute promyelocytic leukemia: long term follow up of the New York Study. Cancer Chemother. Pharmacy] (1997) 40(Suppl.):S25–S29.
   Google Scholar
• MANDELLI F, DIVIERO D, AVVISATI G et al.: Molecular remission in PML/RAR a-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood (1997) 90(3):1014–1021.
   Google Scholar
• SHEN ZX, CHEN GQ, NI JH et al: Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood (1997) 89(9):3354–3360.
   Google Scholar
• SOIGNET SL, MASLAK P, WANG ZG et al.: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl. J. Med. (1998) 339(19):1341–1348.
   PubMed Web of Science ®Google Scholar
• ••First study to show that low doses of ATOcan induce complete remissions in patients with relapsed APL.
   Google Scholar
• FENAUX P, CHASTANG C, CHEVRET S et al.: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood (1999) 94(4):1192–1200.
   Google Scholar
• •A large study, whose findings strongly suggest that the early addition of chemotherapy to ATRA and maintenance therapy combining continuous CT and intermittent ATRA can reduce the incidence of relapse in APL.
   Google Scholar
• WARRELL RP, DE THE H, WANG ZY et al.: Acute promyelocytic leukemia. N. Engl. J. Med. (1993) 329(3):177–189.
   PubMed Web of Science ®Google Scholar
• •Fairly thorough review article of APL.
   Google Scholar
• GRIGNANI F, FAGIOLI M, ALCALAY M et al.: Acute promyelocytic leukemia: from genetics to treatment. Blood (1994) 83(1):10–25.
   PubMedGoogle Scholar
• LO COCO F, DIVIERO D, FALINI B et al.: Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood(1999) 94(1):12–22.
   PubMed Web of Science ®Google Scholar
• •Thorough review of molecular pathogenesis of APL and molecular monitoring.
   Google Scholar
• GOLOMB HM, ROWLEY JD, VARDIMAN JW et al.: `Microgranulai acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cytogenetic entity. Blood (1980) 55(2):253–259.
   PubMedGoogle Scholar
• MCKENNA RW, PARKIN J, BLOOMFIELD CD et al.: Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant. Br: J. Haematol. (1982) 50(2):201–214.
   PubMedGoogle Scholar
• ROVELLI A, BIONDI A, CANTU A et al.: Microgranular variant of acute promyelocytic leukemia in children. J. Clin. Oncol. (1992) 10(9):1413–1418.
   PubMedGoogle Scholar
• CASTOLDI GL, LISO V, SPECCHIA G et al.: Acute promyelocytic leukemia: morphological aspects. Leukemia (1994) 8\(Suppl. 2):S27–S32.
   Google Scholar
• DE THE H, LAVAU C, MARCHIO A et al.: The PML-PAR-a fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered PAR. Cell (1991) 66(4):675–684.
   PubMed Web of Science ®Google Scholar
• KAKIZUKA A, MILLER WH, UMISONO K et al.: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses PAR-a with a novel putative transcription factor, PML. Cell (1991) 66(4):663–674.
   PubMed Web of Science ®Google Scholar
• MELNICK A, LICHT JD: Deconstructing a disease: PAR-a, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood, (1999) 93(10):3167–3215.
   PubMed Web of Science ®Google Scholar
• ••A very good review of the understanding ofmolecular pathogenesis of APL.
   Google Scholar
• DYCK JA, MAUL GG, MILLER WH, CHEN JD, KAKINZUKA A, EVANS RM: A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell (1994) 76(2):333–343.
   PubMedGoogle Scholar
• KOKEN MH, PUVION-DUTILLUEL F, GUILLEMIN MC et al.: The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO (1994) 13:1073–1083.
   PubMed Web of Science ®Google Scholar
• WANG ZG, RUGGERO D, RONCHETTI S et al.: PML is essential for multiple apoptotic pathways. Nat. Genet. (1998) 20(3):266–272.
   PubMed Web of Science ®Google Scholar
• ZHONG S, SALOMONI P, PANDOLFI PP: The transcriptional role of PML and the nuclear body. Nat. Cell Biol. (2000) 2(5):E85–E90.
   Google Scholar
• HE LZ, GUIDEZ F, TRIBIOLI C et al.: Distinct interactions of PML-PAR-a and PLZF-PAR-a with co-repressors determine differential responses to RA in APL. Nat. Genet. (1998) 18(2):126–135.
   PubMedGoogle Scholar
• PEREZ A, KASTNER P, SETHI S, LUTZ Y, REIBEL C, CHAMBON P: PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO (1993) 12(8):3171–3182.
   PubMedGoogle Scholar
• ZHONG S, MULLER S, RONCHETTI S, FREEMONT PS, DEJEAN A, PANDOLFI PP: Role of SUMO-1-modified PML in nuclear body formation. Blood (2000) 95(9):2748–2752.
   PubMed Web of Science ®Google Scholar
• ALTUCCI L, GRONEMEYER H: The promise of retinoids to fight against cancer. Nat. Rev Cancer (2001) 1(3):181–193.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of the therapeuticeffect of retinoids and an explanation of the different mechanisms of action in APL.
   Google Scholar
• BACHLEITNER-HOFMANN T, KEES M, GISSLINGER H et al.: Arsenic trioxide: acute promyelocytic leukemia and beyond. Leuk. Lymphoma (2002) 43(8):1535–1540.
   PubMed Web of Science ®Google Scholar
• ZHAO WL, CHEN SJ, SHEN Y et al.: Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies. Leuk. Lymphoma (2001) 42(6):1265–1273.
   PubMed Web of Science ®Google Scholar
• GRIGNANI F, TESTA U, ROGAIA D et al.: Effects on differentiation by the promyelocytic leukemia PML/RAR-a protein depend on the fusion of the PML protein dimerization and PAR-a DNA binding domains. EMBO (1996) 15(18):4949–4958.
   PubMedGoogle Scholar
• LIU TX, ZHANG JW, TAO Jet al.: Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood (2000) 96(4):1496–1504.
   Google Scholar
• CHEN Z, BRAND NJ, CHEN A et al.: Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-a locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO (1993) 12(3):1161–1167.
   PubMedGoogle Scholar
• ARNOULD C, PHILIPPE C, BOURDON V, GREGOIRE MJ, BERGER R, JONVEAUX P: The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor-a in acute promyelocytic-like leukaemia. Hum. MM. Genet. (1999) 8(9):1741–1749.
   PubMedGoogle Scholar
• GIANNI M, PONZANELLI I, MOLOGNI L et al.: Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. Cell Death Differ. (2000) 7(5):447–460.
   PubMedGoogle Scholar
• KAMBHAMPATI S, VERMA A, LI YZ, PARMAR S, SASSANO A, PLATANIAS L: Signalling pathways activated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Leuk. Lymphoma (2003) (Submitted).
   Google Scholar
• •Recent update on signal transduction induced by ATRA in APL.
   Google Scholar
• HUANG W, SUN GL, LI XS et al.: Acute promyelocytic leukemia: clinical relevance of two major PML-PAR-a isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood (1993) 82(4):1264–1269.
   PubMed Web of Science ®Google Scholar
• MILLER WH, KAKIZUKA A, FRANKEL SR et al.: Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor a clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc. Nati Acad. ScL USA (1992) 89(7)2694–2698.
   Google Scholar
• CASTAIGNE S, BALITRAND N, DE THE H, DEJEAN A, DEGOS L, CHOMIENNE C: A PML/retinoic acid receptor-a fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood (1992) 79(12):3110–3115.
   PubMed Web of Science ®Google Scholar
• GRIMWADE, D: The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. &J. Haematol (1999) 106(3):591–613.
   PubMedGoogle Scholar
• LO COCO F, DIVERIO D, D'ADAMO F et al.: PML/RAR-a rearrangement in acute promyelocytic leukaemias apparently lacking the t(15;17) translocation. Eur. Haematol (1992) 48(3):173–176.
   Google Scholar
• IKEDA K, SASAKI K, TASAKA T et al: Detection of PML-retinoic acid receptor-a fusion transcripts in acute promyelocytic leukemia with trisomy 8 but without t(15;17). Am. J. Hematol (1994) 45(3):212–216.
   PubMedGoogle Scholar
• HIORNS LR, MINT, SWANSBURY GJ, ZELENT A, DYER MJ, CATOVSKY D: Interstitial insertion of retinoic acid receptor-a gene in acute promyelocytic leukemia with normal chromosomes 15 and 17. Blood(1994) 83(10):2946–2951.
   PubMedGoogle Scholar
• GRIMWADE D, HOWE K, LANGABEUR S et al.: Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. M.R.C. Adult Leukaemia Working Party. Br. Haematol (1996) 94(3):557–573.
   Google Scholar
• GRIMWADE D, GORMAN P, DUPREZ E et al.: Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood (1997) 90(12):4876–4885.
   PubMedGoogle Scholar
• DYCK JA, WARELL RP, EVANS PM, MILLER WH: Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-a protein. Blood (1995) 86(3):862–867.
   PubMedGoogle Scholar
• FALINI B, FLENGHI L, FAGIOLI M et al.: Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood(1997) 90(10):4046–4053.
   PubMed Web of Science ®Google Scholar
• FENAUX P, CHOMIENNE C, DEGOS L et al.: Acute promyelocytic leukemia: biology and treatment. Semin. Oncol (1997) 24(1):92–102.
   PubMedGoogle Scholar
• WIERNIK PH, TALLMAN MS: Diagnosis and treatment of acute promyelocytic leukemia In: Neoplastic diseases of the blood, (3-d edn.), Wiernik PH, Dutcher JP, Kyle RA (Eds), Churchill Livingstone, New York, USA (1996):533–580.
   Google Scholar
• LO COCO F, NERVI C, AVVISATI G, MANDELLI F: Acute promyelocytic leukemia: a curable disease. Leukemia (1998) 12(12):1866–1880.
   PubMed Web of Science ®Google Scholar
• FRANKEL SR, POWELL BL: Current approaches to promyelocytic leukemia. In: Diagnostic and Therapeutic Advances in Hematological Malignancies, Gordon L, Tallman MS (Eds), (1999) Kluwer, Boston, USA (1999):125–153.
   Google Scholar
• ASOU N, ADACHI K, TAMURA J et al: Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group." Clin. Oncol (1998) 16(1):78–85.
   Google Scholar
• •A multi-centre study of 196 patients, which shows that age, haemorrhagic diathesis, and initial leukocyte count are prognostic factors for APL, treated with ATRA followed by intensive chemotherapy.
   Google Scholar
• BURNETT AK, GRIMWADE D, SALOMON E, WHEATLEY K, GOLDSTONE AH: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood (1999) 93(12):4131–4143.
   PubMed Web of Science ®Google Scholar
• •A large, randomised study that evaluated the role of extended therapy with ATRA and presenting white count as a prognostic factor.
   Google Scholar
• TALLMAN MS, ANDERSEN JW, SCHIFFER CA et al.: All-trans retinoic acid in acute promyelocytic leukemia: long term outcome results and prognostic factor analysis from intergroup protocol 0129. Blood (1999) 94 (10 Suppl. 1):698a (Abstract).
   Google Scholar
• CHOU WC, TANG JL, YAO M et al.: Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment. Leukemia (1997) 11(7):921–928.
   PubMedGoogle Scholar
• OHNO R, KANAMARU A, MIYAKAWI S et al.: The JALSG APL92 Study for newly diagnosed acute promyelocytic leukemia(APL) Analysis of prognostic factors to increase cure rate in the next stud. Blood (1999) 94:2262a (Abstract).
   Google Scholar
• SANZ MA, LO COCO F, MARTIN G et al.: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood (2000) 96(4):1247–1253.
   PubMed Web of Science ®Google Scholar
• ••A combination of data from two largestudies, that shows the omission of nonanthracycline drugs from the consolidation regimen is not associated with reduced antileukemic efficacy, and a simple predictive model may be used for risk-adapted therapy in this disease.
   Google Scholar
• MORENO I, MARTIN G, BOLUFER P et al.: Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica (2003) 88(1):19–24.
   PubMed Web of Science ®Google Scholar
• KOTTARIDIS PD, GALE RE, FREW ME et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood (2001) 98(6):1752–1759.
   PubMed Web of Science ®Google Scholar
• THIEDE C, STEUDEL C, MOHR B et al.: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood (2002) 99(12):4326–4335.
   PubMed Web of Science ®Google Scholar
• SCHNITTGER S, SCHOCH C, DUGAS M et al.: Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood (2002) 100(1):59–66.
   PubMed Web of Science ®Google Scholar
• SLACK JL, ARTHUR DC, LAWRENCE D: Secondary cytogenetic changes in acute promyelocytic leukemia-prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. Clin. °nail (1997) 15(5):1786–1795.
   PubMedGoogle Scholar
• HERNANDEZ JM, MARTIN G, GUTIERREZ NC et al: Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracycline based protocol. A report of the Spanish group PETHEMA. Haematologica (2001) 86(8):807–813.
   Google Scholar
• DE BOTTON S, CHEVRET S, SANZ M et al.: Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br. Haematol. (2000) 111(3):801–806.
   PubMed Web of Science ®Google Scholar
• HIORNS LR, SWANSBURY GJ, MEHTAJ et al.: Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br. Haematol. (1997) 96(2):314–321.
   PubMedGoogle Scholar
• XU L, ZHAO WL, XIONG SM et al: Molecular cytogenetic characterization and clinical relevance of additional, complex and/or variant chromosome abnormalities in acute promyelocytic leukemia. Leukemia (2001) 15(9):1359–1368.
   PubMedGoogle Scholar
• MURRAY CK, ESTEY E, PAIETTA E et al.: CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? Clin. Omni (1999) 17(1):293–297.
   Google Scholar
• FERRARA F, MORABITO F, MARTINO B et al: CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin. Omni (2000) 18(6):1295–1300.
   PubMed Web of Science ®Google Scholar
• GUGLIELMI C, MARTELLI MP, DIVERIO D et al.: Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br. Haematol. (1998) 102(4):1035–1041.
   Google Scholar
• AVVISATI G, MANDELLI F, PETTI MC et al.: Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Haematol. (1990) 44(4):257–260.
   Google Scholar
• PAIETTA E, ANDERSEN J, RACEVSKISJ et al: Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia (1994) 8(6):968–973.
   PubMed Web of Science ®Google Scholar
• MICHIELI M, DAMIANI D, ERMACORA A et al.: P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia. Br. Haematol. (2000) 108(4):703–709.
   PubMed Web of Science ®Google Scholar
• TAKESHITA A, SHINJO K, NAITO K et al.: Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA. Haematol. (2000) 108(1):90–92.
   Google Scholar
• DEGOS L, CHOMIENNE C, DANIEL MT et al.: Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet (1990) 336(8728):1440–1441.
   PubMed Web of Science ®Google Scholar
• VAJDAT L, MASLAK P, MLLER WH et al.: Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-a isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood (1994) 84(11):3843–3849.
   PubMedGoogle Scholar
• TALLMAN MS, ANDERSEN JW, SCHIFFER CA et al: Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood (2000) 95(1):90–95.
   PubMed Web of Science ®Google Scholar
• •This reports the incidence, clinical course, and outcome of patients with newly diagnosed APL who developed the RAS treated on the Intergroup Protocol 0129.
   Google Scholar
• DE BOTTON S, DOMBRET H, SANZ M et al: Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood (1998) 92(8):2712–2718.
   Google Scholar
• ••The first large study to show that theoccurrence of ATRA syndrome was associated with lower EFS and survival.
   Google Scholar
• SANZ MA, MARTIN G, RAYON C et al: A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR-a-positive acute promyelocytic leukemia. PETHEMA group. Blood (1999) 94(9):3015–3021.
   PubMed Web of Science ®Google Scholar
• FENAUX P, TERTIAN G, CASTAIGNE S et al: A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. J. Clin. Oncol. (1991) 9(9):1556–1561.
   PubMedGoogle Scholar
• ESTEY E, THALL PF, PIERCE S, KANTARJIAN H, KEATING M: Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. Clin. Oncol. (1997) 15(2):483–490.
   Google Scholar
• •This study shows that omission of cytarabine (Ara-C) from treatment of newly diagnosed APL, allows administration of more anthracycline leading to similar CR rates with combination therapy.
   Google Scholar
• ESTEY EH, GILES FJ, BERAN M et al: Experience with gemtuzumab ozogamicin (IVIylotarg) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood (2002) 99(11):4222–4224.
   PubMed Web of Science ®Google Scholar
• •A small study, showing that initial induction therapy with combination of ATRA and Mylotare" leads to high CR rates comparable to combination of ATRA with chemotherapy.
   Google Scholar
• BARBUI T, FALANGA A: The management of bleeding and thrombosis in leukemia. In: Leukemia, (6h edn.), Henderson ES, Greaves MF (Eds), Philadelphia, PA, USA. (1996):291.
   Google Scholar
• TALLMAN MS, HAKIMIAN D, KWAAN HC, RICKLES FR: New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia. Leak. Lymphoma (1993) 11(1-2):27–36.
   PubMed Web of Science ®Google Scholar
• •An excellent review of coagulopathy in APL.
   Google Scholar
• FENAUX P, LE DELEY MC, CASTAIGNE S et al.: Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood (1993) 82(11):3241–3249.
   Google Scholar
• •An important study reconfirming role of ATRA in induction therapy for APL.
   Google Scholar
• DI BONA E, AVVISATI G, CASTAMAN G et al.: Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br. Haematol. (2000) 108(4):689–695.
   PubMed Web of Science ®Google Scholar
• FALANGA A, IACOVIELLO L, EVANGELISTA V et al.: Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid. Blood (1995) 86(3):1072–1081.
   PubMedGoogle Scholar
• DOMBRET H, SCROBOHACI ML, GHORRA P et al.: Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia (1993) 7(1):2–9.
   PubMed Web of Science ®Google Scholar
• KAWAI Y, WANTABE K, KIZAKI M et al.: Rapid improvement of coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia. Am. Hematol (1994) 46(3):184–188.
   PubMedGoogle Scholar
• BARBUI T, FINAZZI G, FALANGA A: The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood (1998) 91(9):3093–3102.
   PubMed Web of Science ®Google Scholar
• FALANGA A, CONSONNI R, MARCHETTI M et al: Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid. Leukemia (1994) 8(1):156–159.
   PubMedGoogle Scholar
• KOYAMA T, HIROSAWA S, KAWAMATA N, TOHDA S, AOKI N: All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood (1994) 84(9):3001–3009.
   PubMedGoogle Scholar
• ISHII H, HORIE S, KIZAKI K, KAZAMA M: Retinoic acid counteracts both the downregulation of thrombomodulin and the induction of tissue factor in cultured human endothelial cells exposed to tumor necrosis factor. Blood (1992) 80(10):2556–2562.
   PubMedGoogle Scholar
• FRANKEL SR, EARDLEY A, HELLER G et al.: All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann. Intern. Med. (1994) 120(4):278–286.
   Google Scholar
• •This study emphasises on the role of post remission consolidation with ATRA in patients with APL, and described the `retinoic acid syndrome'.
   Google Scholar
• FRANKEL SR, EARDLEY A, LAUWERS G, WEISS M, WARRELL RP: The `retinoic acid syndrome' in acute promyelocytic leukemia. Ann. Intern. Med. (1992) 117(4):292–296.
   PubMed Web of Science ®Google Scholar
• ••This study described RAS for the first timeand role of high dose dexarnethasone for its treatment.
   Google Scholar
• KO BS, TANG JL, CHEN YC et al.: Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia-the occurrence of retinoic acid syndrome is a risk factor. Leukemia (1999) 13(9):1406–1408.
   PubMedGoogle Scholar
• WEISS MA, WARRELL RP: Two cases of extramedullary acute promyelocytic leukemia. Cytogenetics, molecular biology, and phenotypic and clinical studies. Cancer (1994) 74(7):1882–1886.
   Google Scholar
• WIERNIK PH, DE BELLIS R, MUXI P, DUTCHER JP: Extramedullary acute promyelocytic leukemia. Cancer (1996) 78(12):2510–2514.
   PubMed Web of Science ®Google Scholar
• LISO V, SPECCHIA G, POGLIANI EM et al.: Extramedullary involvement in patients with acute promyelocytic leukemia: a report of seven cases. Cancer (1998) 83(8):1522–1528.
   PubMedGoogle Scholar
• EVANS GD, GRIMWADE DJ: Extramedullary disease in acute promyelocytic leukemia. Leak. Lymphoma (1999) 33(3-4):219–229.
   PubMed Web of Science ®Google Scholar
• AVVISATI G, LO COCO F, DIVERIO D et al.: AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italian° Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood (1996) 88(4):1390–1398.
   PubMed Web of Science ®Google Scholar
• WILEY JS, FIRKIN FC: Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia (1995) 9(5):774–778.
   Google Scholar
• FIRKIN FC, BRADSTOCK KF, WILEY JS et al.: A Phase II study of all-trans retinoic acid (ATRA) with prednisone prophylaxis in the treatment of acute promyelocytic leukemia (APL). Proc. Am. Soc. Clin. Oncol (1999) 94:4225a.
   Google Scholar
• DI BONA E, AVVISATI G, GUGLIOTTA L, for the GIMEMA group: Hemostasis related early morbidity and mortality during remission induction treatment with or without all-trans-retinoic acid (ATRA) in acute promyelocytic leukemia. Blood (1997) 90\(Suppl. 1):331a.
   Google Scholar
• SEALE J, DELVA L, RENESTO P et al: All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia. Leukemia (1996) 10(1):95–101.
   PubMedGoogle Scholar
• LARSON RS, BROWN DC, SKLAR LA: Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood (1997) 90(7):2747–2756.
   PubMed Web of Science ®Google Scholar
• BROWN DC, TSUJI H, LARSON RS: All-trans retinoic acid regulates adhesion mechanism and transmigration of the acute promyelocytic leukaemia cell line NB-4 under physiologic flow. Br. J. Haematol (1999) 107(1):86–98.
   PubMedGoogle Scholar
• DUBIOS C, SCHLAGETER MH, DE GENTILE A et al.: Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells. Blood (1994) 83(11):3264–3270.
   Google Scholar
• LENGFELDER E, RIECHERT A, SCHOCH C et al.: Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia (2000) 14(8):1362–1370.
   PubMedGoogle Scholar
• FENAUX P, CASTAIGNE S, DOMBRET H et al.: All-transmtinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood (1992) 80(9):2176–2181.
   PubMed Web of Science ®Google Scholar
• ROWE JM: Uncertainties in the standard care of acute myelogenous leukemia. Leukemia (2001) 15(4):677–679.
   PubMedGoogle Scholar
• DIVERIO D, ROSSI V, AVVISATI G et al.: Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RAR-a fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter AIDA' trial. GIMEMA-AIEOP Multicenter 'AIDA' Trial. Blood(1998) 92(3):784–789.
   Google Scholar
• LO COCO F, DIVIERO D, AVVISATI G et al.: Therapy of molecular relapse in acute promyelocytic leukemia. Blood (1999) 94(7):2225–2229.
   PubMed Web of Science ®Google Scholar
• •This study suggests that early administration of salvage therapy is advantageous in APL and represents the first experience on therapy of molecular relapse in acute leukemia.
   Google Scholar
• TOBAL K, SAUNDERS MJ, GREY MR, YIN JA: Persistence of PAR a-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia. Br. Haematol (1995) 90(3):615–618.
   PubMedGoogle Scholar
• WANG Z, SHEN Z, CHEN S et al: Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10 year experience of its application. Chin Med (1999) 112:963–967.
   Google Scholar
• FRANKELL SR: Current approaches to acute promyelocytic leukemia. In: Diagnostic and therapeutic advances in hematologic malignancies, Tallman MS (Ed.) Kluwer, Boston, USA (1999) 125–153.
   Google Scholar
• ZHANG P, WANG SY, HU LH et al: Arsenic trioxide treated 72 cases of promyelocytic leukemia. ChM J Hematol (1996) 17:58–62.
   Google Scholar
• NIU C, YAN H, YU T et al: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood (1999) 94(10):3315–3324.
   PubMed Web of Science ®Google Scholar
• DOMBRET H, FENAUX P, SOIGNET SL, TALLMAN MS: Established practice in the treatment of patients with acute promyelocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin. Hematol (2002) 39(2 Suppl. 1):8–13.
   Google Scholar
• CAMACHO LH, SOIGNET SL, CHANEL S et al: Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J. Clin. Oncol (2000) 18(13):2620–2625.
   PubMed Web of Science ®Google Scholar
• MANDELLI F, LABOPIN M, GRANENA A et al.: European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Working Party on Acute Leukemia of the European Cooperative Group for Bone Marrow Transplantation (EMBT). Bone Marrow Transplant. (1994) 14(2):293–298.
   PubMedGoogle Scholar
• •Gives an insight on role of BMT in APL.
   Google Scholar
• MELONI G, DIVIERO D, VIGNETTI M et al.: Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR-a fusion gene. Blood (1997) 90(3):1321–1325.
   PubMedGoogle Scholar
• DE BOTTON S, FAWAZ A, CHEVRET S et al.: Autologous and allogeneic stem cell transplant (SCT) in second CR (CR2) in acute promyelocytic leukemia (APL) initially treated with ATRA: European APL group experience. Blood (2002) 100(11):217a (Abstract).
   Google Scholar
• ROMAN J, MARTIN C, TORRES A et al: Absence of detectable PML-RAR a fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia. Bone Marrow Transplant (1997) 19(7):679–683.
   PubMedGoogle Scholar
• SANZ MA, DE LA RUBIA J, BONANAD S et al.: Prolonged molecular remission after PML/RAR a-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft? Leukemia (1998) 12(6):992–995.
   Google Scholar
• DE BOTTON S, CHEVRET S, SANZ M et al.: Additional chromosomal abnormalities have no effect on the clinical outcome of patients with acute promyelocytic leukemia (APL). Blood (1999) 94(10, Suppl. 1):695a (Abstract).
   Google Scholar
• HUANG SL, GUO Al, XIANG Y et al: Clinical study on the treatment of acute promyelocytic leukemia mainly with Composite Indigo Naturalis tablets. Chin. Hematol (1995) 16:26–28.
   Google Scholar
• SOIGNET SL, FRANKEL S, TALLMAN MS et al.: Multiple centers of trial of arsenic trioxide in acute promyelocytic leukemia (APL). Blood (1999) 94(10 Suppl. 1):698a (Abstract).
   Google Scholar